Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
21
BRTX Quote, Financials, Valuation and Earnings
Last price:
$1.21
Seasonality move
:
13.74%
Day range:
$1.11 - $1.20
52-week range:
$0.98 - $2.55
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
26.36x
P/B ratio:
4.94x
Volume:
26.7K
Avg. volume:
57.3K
1-year change:
-18.12%
Market cap:
$10.8M
Revenue:
$401K
EPS (TTM):
-$1.51
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BRTX
BioRestorative Therapies, Inc.
|
$150K | -$0.35 | 246.42% | -48.05% | $13.00 |
|
AIM
AIM ImmunoTech
|
-- | -$0.09 | -23.08% | -53.85% | $4.50 |
|
CVM
CEL-SCI Corp.
|
-- | -- | -- | -- | $42.50 |
|
IGC
IGC Pharma, Inc.
|
$193K | -$0.02 | -24.9% | -15.25% | $3.88 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
TOI
The Oncology Institute, Inc.
|
$139.8M | -$0.10 | 39.41% | -52.63% | $6.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BRTX
BioRestorative Therapies, Inc.
|
$1.22 | $13.00 | $10.8M | -- | $0.00 | 0% | 26.36x |
|
AIM
AIM ImmunoTech
|
$0.04 | $4.50 | $2.8M | -- | $0.00 | 0% | 13.27x |
|
CVM
CEL-SCI Corp.
|
$5.15 | $42.50 | $15.6M | -- | $0.00 | 0% | -- |
|
IGC
IGC Pharma, Inc.
|
$0.29 | $3.88 | $27M | -- | $0.00 | 0% | 21.84x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$5.87 | $0.85 | $739.7M | 9.86x | $0.80 | 0% | 11.41x |
|
TOI
The Oncology Institute, Inc.
|
$3.67 | $6.50 | $361.1M | -- | $0.00 | 0% | 0.68x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BRTX
BioRestorative Therapies, Inc.
|
-- | 0.341 | -- | 1.31x |
|
AIM
AIM ImmunoTech
|
48.41% | 0.745 | 17.25% | 0.71x |
|
CVM
CEL-SCI Corp.
|
37.03% | 0.660 | 33.61% | 2.14x |
|
IGC
IGC Pharma, Inc.
|
1.82% | 0.713 | 0.39% | 0.78x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | -3.190 | 8.08% | 1.85x |
|
TOI
The Oncology Institute, Inc.
|
113.45% | -0.225 | 30.41% | 1.33x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BRTX
BioRestorative Therapies, Inc.
|
-$51.4K | -$3.7M | -199.46% | -199.72% | -31432.2% | -$2.9M |
|
AIM
AIM ImmunoTech
|
$27K | -$4.5M | -219.06% | -256.33% | -9994.29% | -$3.3M |
|
CVM
CEL-SCI Corp.
|
-$960.8K | -$6M | -117.93% | -230.36% | -- | -$4.7M |
|
IGC
IGC Pharma, Inc.
|
-$6K | -$2.9M | -91.27% | -94.42% | -1517.8% | -$2.4M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
TOI
The Oncology Institute, Inc.
|
$17.2M | -$8.1M | -48.97% | -9486.64% | -5.9% | -$13.2M |
BioRestorative Therapies, Inc. vs. Competitors
-
Which has Higher Returns BRTX or AIM?
AIM ImmunoTech has a net margin of -25748.31% compared to BioRestorative Therapies, Inc.'s net margin of -10571.43%. BioRestorative Therapies, Inc.'s return on equity of -199.72% beat AIM ImmunoTech's return on equity of -256.33%.
Company Gross Margin Earnings Per Share Invested Capital BRTXBioRestorative Therapies, Inc.-435.59% -$0.33 $2.2M AIMAIM ImmunoTech77.14% -$0.06 $5.6M -
What do Analysts Say About BRTX or AIM?
BioRestorative Therapies, Inc. has a consensus price target of $13.00, signalling upside risk potential of 965.57%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than BioRestorative Therapies, Inc., analysts believe AIM ImmunoTech is more attractive than BioRestorative Therapies, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BRTXBioRestorative Therapies, Inc.1 0 0 AIMAIM ImmunoTech1 0 0 -
Is BRTX or AIM More Risky?
BioRestorative Therapies, Inc. has a beta of 0.181, which suggesting that the stock is 81.9% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.
-
Which is a Better Dividend Stock BRTX or AIM?
BioRestorative Therapies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioRestorative Therapies, Inc. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BRTX or AIM?
BioRestorative Therapies, Inc. quarterly revenues are $11.8K, which are smaller than AIM ImmunoTech quarterly revenues of $35K. BioRestorative Therapies, Inc.'s net income of -$3M is higher than AIM ImmunoTech's net income of -$3.7M. Notably, BioRestorative Therapies, Inc.'s price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioRestorative Therapies, Inc. is 26.36x versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BRTXBioRestorative Therapies, Inc.26.36x -- $11.8K -$3M AIMAIM ImmunoTech13.27x -- $35K -$3.7M
-
Which has Higher Returns BRTX or CVM?
CEL-SCI Corp. has a net margin of -25748.31% compared to BioRestorative Therapies, Inc.'s net margin of --. BioRestorative Therapies, Inc.'s return on equity of -199.72% beat CEL-SCI Corp.'s return on equity of -230.36%.
Company Gross Margin Earnings Per Share Invested Capital BRTXBioRestorative Therapies, Inc.-435.59% -$0.33 $2.2M CVMCEL-SCI Corp.-- -$0.76 $25.3M -
What do Analysts Say About BRTX or CVM?
BioRestorative Therapies, Inc. has a consensus price target of $13.00, signalling upside risk potential of 965.57%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 725.24%. Given that BioRestorative Therapies, Inc. has higher upside potential than CEL-SCI Corp., analysts believe BioRestorative Therapies, Inc. is more attractive than CEL-SCI Corp..
Company Buy Ratings Hold Ratings Sell Ratings BRTXBioRestorative Therapies, Inc.1 0 0 CVMCEL-SCI Corp.1 0 0 -
Is BRTX or CVM More Risky?
BioRestorative Therapies, Inc. has a beta of 0.181, which suggesting that the stock is 81.9% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.538, suggesting its less volatile than the S&P 500 by 46.183%.
-
Which is a Better Dividend Stock BRTX or CVM?
BioRestorative Therapies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioRestorative Therapies, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BRTX or CVM?
BioRestorative Therapies, Inc. quarterly revenues are $11.8K, which are larger than CEL-SCI Corp. quarterly revenues of --. BioRestorative Therapies, Inc.'s net income of -$3M is higher than CEL-SCI Corp.'s net income of -$6.1M. Notably, BioRestorative Therapies, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioRestorative Therapies, Inc. is 26.36x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BRTXBioRestorative Therapies, Inc.26.36x -- $11.8K -$3M CVMCEL-SCI Corp.-- -- -- -$6.1M
-
Which has Higher Returns BRTX or IGC?
IGC Pharma, Inc. has a net margin of -25748.31% compared to BioRestorative Therapies, Inc.'s net margin of -953.4%. BioRestorative Therapies, Inc.'s return on equity of -199.72% beat IGC Pharma, Inc.'s return on equity of -94.42%.
Company Gross Margin Earnings Per Share Invested Capital BRTXBioRestorative Therapies, Inc.-435.59% -$0.33 $2.2M IGCIGC Pharma, Inc.-3.14% -$0.02 $8.2M -
What do Analysts Say About BRTX or IGC?
BioRestorative Therapies, Inc. has a consensus price target of $13.00, signalling upside risk potential of 965.57%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.88 which suggests that it could grow by 1231.62%. Given that IGC Pharma, Inc. has higher upside potential than BioRestorative Therapies, Inc., analysts believe IGC Pharma, Inc. is more attractive than BioRestorative Therapies, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BRTXBioRestorative Therapies, Inc.1 0 0 IGCIGC Pharma, Inc.2 0 0 -
Is BRTX or IGC More Risky?
BioRestorative Therapies, Inc. has a beta of 0.181, which suggesting that the stock is 81.9% less volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.322, suggesting its less volatile than the S&P 500 by 67.78%.
-
Which is a Better Dividend Stock BRTX or IGC?
BioRestorative Therapies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioRestorative Therapies, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BRTX or IGC?
BioRestorative Therapies, Inc. quarterly revenues are $11.8K, which are smaller than IGC Pharma, Inc. quarterly revenues of $191K. BioRestorative Therapies, Inc.'s net income of -$3M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, BioRestorative Therapies, Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioRestorative Therapies, Inc. is 26.36x versus 21.84x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BRTXBioRestorative Therapies, Inc.26.36x -- $11.8K -$3M IGCIGC Pharma, Inc.21.84x -- $191K -$1.8M
-
Which has Higher Returns BRTX or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -25748.31% compared to BioRestorative Therapies, Inc.'s net margin of -255.85%. BioRestorative Therapies, Inc.'s return on equity of -199.72% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital BRTXBioRestorative Therapies, Inc.-435.59% -$0.33 $2.2M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About BRTX or NBY?
BioRestorative Therapies, Inc. has a consensus price target of $13.00, signalling upside risk potential of 965.57%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -85.52%. Given that BioRestorative Therapies, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe BioRestorative Therapies, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BRTXBioRestorative Therapies, Inc.1 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is BRTX or NBY More Risky?
BioRestorative Therapies, Inc. has a beta of 0.181, which suggesting that the stock is 81.9% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.
-
Which is a Better Dividend Stock BRTX or NBY?
BioRestorative Therapies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. BioRestorative Therapies, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BRTX or NBY?
BioRestorative Therapies, Inc. quarterly revenues are $11.8K, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. BioRestorative Therapies, Inc.'s net income of -$3M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, BioRestorative Therapies, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 9.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioRestorative Therapies, Inc. is 26.36x versus 11.41x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BRTXBioRestorative Therapies, Inc.26.36x -- $11.8K -$3M NBYNovaBay Pharmaceuticals, Inc.11.41x 9.86x $521K -$1.3M
-
Which has Higher Returns BRTX or TOI?
The Oncology Institute, Inc. has a net margin of -25748.31% compared to BioRestorative Therapies, Inc.'s net margin of -10.08%. BioRestorative Therapies, Inc.'s return on equity of -199.72% beat The Oncology Institute, Inc.'s return on equity of -9486.64%.
Company Gross Margin Earnings Per Share Invested Capital BRTXBioRestorative Therapies, Inc.-435.59% -$0.33 $2.2M TOIThe Oncology Institute, Inc.12.59% -$0.14 $91.3M -
What do Analysts Say About BRTX or TOI?
BioRestorative Therapies, Inc. has a consensus price target of $13.00, signalling upside risk potential of 965.57%. On the other hand The Oncology Institute, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 77.11%. Given that BioRestorative Therapies, Inc. has higher upside potential than The Oncology Institute, Inc., analysts believe BioRestorative Therapies, Inc. is more attractive than The Oncology Institute, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BRTXBioRestorative Therapies, Inc.1 0 0 TOIThe Oncology Institute, Inc.3 0 0 -
Is BRTX or TOI More Risky?
BioRestorative Therapies, Inc. has a beta of 0.181, which suggesting that the stock is 81.9% less volatile than S&P 500. In comparison The Oncology Institute, Inc. has a beta of 0.151, suggesting its less volatile than the S&P 500 by 84.902%.
-
Which is a Better Dividend Stock BRTX or TOI?
BioRestorative Therapies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Oncology Institute, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioRestorative Therapies, Inc. pays -- of its earnings as a dividend. The Oncology Institute, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BRTX or TOI?
BioRestorative Therapies, Inc. quarterly revenues are $11.8K, which are smaller than The Oncology Institute, Inc. quarterly revenues of $136.6M. BioRestorative Therapies, Inc.'s net income of -$3M is higher than The Oncology Institute, Inc.'s net income of -$13.8M. Notably, BioRestorative Therapies, Inc.'s price-to-earnings ratio is -- while The Oncology Institute, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioRestorative Therapies, Inc. is 26.36x versus 0.68x for The Oncology Institute, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BRTXBioRestorative Therapies, Inc.26.36x -- $11.8K -$3M TOIThe Oncology Institute, Inc.0.68x -- $136.6M -$13.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
55
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
BIDU alert for Jan 5
Baidu, Inc. [BIDU] is down 0.42% over the past day.
Buy
69
KORU alert for Jan 5
Direxion Daily MSCI South Korea Bull 3X Shares [KORU] is up 23.79% over the past day.
Buy
62
BE alert for Jan 5
Bloom Energy Corp. [BE] is up 19.51% over the past day.
